Reduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia

Purpose: To evaluate the reduced transverse relaxation rate (RR2), a new relaxation index which has been shown recently to be primarily sensitive to intracellular ferritin iron, as a means of detecting short‐term changes in myocardial storage iron produced by iron‐chelating therapy in transfusion‐de...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of magnetic resonance imaging 2011-06, Vol.33 (6), p.1510-1516
Hauptverfasser: Cheung, Jerry S., Au, Wing-Yan, Ha, Shau-Yin, Kim, Daniel, Jensen, Jens H., Zhou, Iris Y., Cheung, Matthew M., Wu, Yin, Guo, Hua, Khong, Pek-Lan, Brown, Truman R., Brittenham, Gary M., Wu, Ed X.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1516
container_issue 6
container_start_page 1510
container_title Journal of magnetic resonance imaging
container_volume 33
creator Cheung, Jerry S.
Au, Wing-Yan
Ha, Shau-Yin
Kim, Daniel
Jensen, Jens H.
Zhou, Iris Y.
Cheung, Matthew M.
Wu, Yin
Guo, Hua
Khong, Pek-Lan
Brown, Truman R.
Brittenham, Gary M.
Wu, Ed X.
description Purpose: To evaluate the reduced transverse relaxation rate (RR2), a new relaxation index which has been shown recently to be primarily sensitive to intracellular ferritin iron, as a means of detecting short‐term changes in myocardial storage iron produced by iron‐chelating therapy in transfusion‐dependent thalassemia patients. Materials and Methods: A single‐breathhold multi‐echo fast spin‐echo sequence was implemented at 3 Tesla (T) to estimate RR2 by acquiring signal decays with interecho times of 5, 9 and 13 ms. Transfusion‐dependent thalassemia patients (N = 8) were examined immediately before suspending iron‐chelating therapy for 1 week (Day 0), after a 1‐week suspension of chelation (Day 7), and after a 1‐week resumption of chelation (Day 14). Results: The mean percent changes in RR2, R2, and R2* off chelation (between Day 0 and 7) were 11.9 ± 8.9%, 5.4 ± 7.7% and −4.4 ± 25.0%; and, after resuming chelation (between Day 7 and 14), −10.6 ± 13.9%, −8.9 ± 8.0% and −8.5 ± 24.3%, respectively. Significant differences in R2 and RR2 were observed between Day 0 and 7, and between Day 7 and 14, with the greatest proportional changes in RR2. No significant differences in R2* were found. Conclusion: These initial results demonstrate that significant differences in RR2 are detectable after a single week of changes in iron‐chelating therapy, likely as a result of superior sensitivity to soluble ferritin iron, which is in close equilibrium with the chelatable cytosolic iron pool. RR2 measurement may provide a new means of monitoring the short‐term effectiveness of iron‐chelating agents in patients with myocardial iron overload. J. Magn. Reson. Imaging 2011;33:1510–1516. © 2011 Wiley‐Liss, Inc.
doi_str_mv 10.1002/jmri.22553
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3098046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>867720630</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4573-8b22231f046641755b3c3c6fc416679410b7c5448d52d999e193d2d5668a6bc13</originalsourceid><addsrcrecordid>eNp9kV1PFDEUhhsjEQRv_AGmd6LJYL87vTEhRBCySLLR4F3T6XSgONOubXdl_73FhY3eeHVOcp7znDYvAK8xOsIIkQ93U_JHhHBOn4E9zAlpCG_F89ojThvcIrkLXuZ8hxBSivEXYJdgrjAiZA-EueuX1vWwJBPyyqXsYHKjuTfFxwCTKQ4ezufkHRxign5apLiqdHYh--JXvqyhD3CKwZeYfLiB0zpak3pvRuhTNdRpuTWjydlN3hyAncGM2b16rPvg2-mnryefm9nV2fnJ8ayxjEvatB0hhOIBMSEYlpx31FIrBsuwEFIxjDppOWNtz0mvlHJY0Z70XIjWiM5iug8-bryLZTe53rpQ_zfqRfKTSWsdjdf_ToK_1TdxpSlSbb1aBW8fBSn-XLpc9OSzdeNogovLrFshJUGCokq-35A2xZyTG7ZXMNIP-eiHfPSffCr85u93bdGnQCqAN8AvP7r1f1T64nJ-_iRtNjs-F3e_3THphxaSSq6vv5xpdT1TF-y70Kf0N2ywq_s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>867720630</pqid></control><display><type>article</type><title>Reduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><creator>Cheung, Jerry S. ; Au, Wing-Yan ; Ha, Shau-Yin ; Kim, Daniel ; Jensen, Jens H. ; Zhou, Iris Y. ; Cheung, Matthew M. ; Wu, Yin ; Guo, Hua ; Khong, Pek-Lan ; Brown, Truman R. ; Brittenham, Gary M. ; Wu, Ed X.</creator><creatorcontrib>Cheung, Jerry S. ; Au, Wing-Yan ; Ha, Shau-Yin ; Kim, Daniel ; Jensen, Jens H. ; Zhou, Iris Y. ; Cheung, Matthew M. ; Wu, Yin ; Guo, Hua ; Khong, Pek-Lan ; Brown, Truman R. ; Brittenham, Gary M. ; Wu, Ed X.</creatorcontrib><description>Purpose: To evaluate the reduced transverse relaxation rate (RR2), a new relaxation index which has been shown recently to be primarily sensitive to intracellular ferritin iron, as a means of detecting short‐term changes in myocardial storage iron produced by iron‐chelating therapy in transfusion‐dependent thalassemia patients. Materials and Methods: A single‐breathhold multi‐echo fast spin‐echo sequence was implemented at 3 Tesla (T) to estimate RR2 by acquiring signal decays with interecho times of 5, 9 and 13 ms. Transfusion‐dependent thalassemia patients (N = 8) were examined immediately before suspending iron‐chelating therapy for 1 week (Day 0), after a 1‐week suspension of chelation (Day 7), and after a 1‐week resumption of chelation (Day 14). Results: The mean percent changes in RR2, R2, and R2* off chelation (between Day 0 and 7) were 11.9 ± 8.9%, 5.4 ± 7.7% and −4.4 ± 25.0%; and, after resuming chelation (between Day 7 and 14), −10.6 ± 13.9%, −8.9 ± 8.0% and −8.5 ± 24.3%, respectively. Significant differences in R2 and RR2 were observed between Day 0 and 7, and between Day 7 and 14, with the greatest proportional changes in RR2. No significant differences in R2* were found. Conclusion: These initial results demonstrate that significant differences in RR2 are detectable after a single week of changes in iron‐chelating therapy, likely as a result of superior sensitivity to soluble ferritin iron, which is in close equilibrium with the chelatable cytosolic iron pool. RR2 measurement may provide a new means of monitoring the short‐term effectiveness of iron‐chelating agents in patients with myocardial iron overload. J. Magn. Reson. Imaging 2011;33:1510–1516. © 2011 Wiley‐Liss, Inc.</description><identifier>ISSN: 1053-1807</identifier><identifier>EISSN: 1522-2586</identifier><identifier>DOI: 10.1002/jmri.22553</identifier><identifier>PMID: 21591022</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Blood Transfusion ; cardiac MR ; Chelating Agents - pharmacology ; chelation therapy ; Chelation Therapy - methods ; Cytosol - metabolism ; Female ; ferritin ; Ferritins - chemistry ; heart ; hemosiderin ; Hemosiderin - chemistry ; Humans ; Iron - chemistry ; iron overload ; Magnetic Resonance Imaging - methods ; Male ; MRI ; Myocardium - pathology ; RR2 ; thalassemia ; Thalassemia - diagnosis ; Thalassemia - pathology ; Time Factors</subject><ispartof>Journal of magnetic resonance imaging, 2011-06, Vol.33 (6), p.1510-1516</ispartof><rights>Copyright © 2011 Wiley‐Liss, Inc.</rights><rights>Copyright © 2011 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4573-8b22231f046641755b3c3c6fc416679410b7c5448d52d999e193d2d5668a6bc13</citedby><cites>FETCH-LOGICAL-c4573-8b22231f046641755b3c3c6fc416679410b7c5448d52d999e193d2d5668a6bc13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmri.22553$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmri.22553$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21591022$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheung, Jerry S.</creatorcontrib><creatorcontrib>Au, Wing-Yan</creatorcontrib><creatorcontrib>Ha, Shau-Yin</creatorcontrib><creatorcontrib>Kim, Daniel</creatorcontrib><creatorcontrib>Jensen, Jens H.</creatorcontrib><creatorcontrib>Zhou, Iris Y.</creatorcontrib><creatorcontrib>Cheung, Matthew M.</creatorcontrib><creatorcontrib>Wu, Yin</creatorcontrib><creatorcontrib>Guo, Hua</creatorcontrib><creatorcontrib>Khong, Pek-Lan</creatorcontrib><creatorcontrib>Brown, Truman R.</creatorcontrib><creatorcontrib>Brittenham, Gary M.</creatorcontrib><creatorcontrib>Wu, Ed X.</creatorcontrib><title>Reduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia</title><title>Journal of magnetic resonance imaging</title><addtitle>J. Magn. Reson. Imaging</addtitle><description>Purpose: To evaluate the reduced transverse relaxation rate (RR2), a new relaxation index which has been shown recently to be primarily sensitive to intracellular ferritin iron, as a means of detecting short‐term changes in myocardial storage iron produced by iron‐chelating therapy in transfusion‐dependent thalassemia patients. Materials and Methods: A single‐breathhold multi‐echo fast spin‐echo sequence was implemented at 3 Tesla (T) to estimate RR2 by acquiring signal decays with interecho times of 5, 9 and 13 ms. Transfusion‐dependent thalassemia patients (N = 8) were examined immediately before suspending iron‐chelating therapy for 1 week (Day 0), after a 1‐week suspension of chelation (Day 7), and after a 1‐week resumption of chelation (Day 14). Results: The mean percent changes in RR2, R2, and R2* off chelation (between Day 0 and 7) were 11.9 ± 8.9%, 5.4 ± 7.7% and −4.4 ± 25.0%; and, after resuming chelation (between Day 7 and 14), −10.6 ± 13.9%, −8.9 ± 8.0% and −8.5 ± 24.3%, respectively. Significant differences in R2 and RR2 were observed between Day 0 and 7, and between Day 7 and 14, with the greatest proportional changes in RR2. No significant differences in R2* were found. Conclusion: These initial results demonstrate that significant differences in RR2 are detectable after a single week of changes in iron‐chelating therapy, likely as a result of superior sensitivity to soluble ferritin iron, which is in close equilibrium with the chelatable cytosolic iron pool. RR2 measurement may provide a new means of monitoring the short‐term effectiveness of iron‐chelating agents in patients with myocardial iron overload. J. Magn. Reson. Imaging 2011;33:1510–1516. © 2011 Wiley‐Liss, Inc.</description><subject>Adult</subject><subject>Blood Transfusion</subject><subject>cardiac MR</subject><subject>Chelating Agents - pharmacology</subject><subject>chelation therapy</subject><subject>Chelation Therapy - methods</subject><subject>Cytosol - metabolism</subject><subject>Female</subject><subject>ferritin</subject><subject>Ferritins - chemistry</subject><subject>heart</subject><subject>hemosiderin</subject><subject>Hemosiderin - chemistry</subject><subject>Humans</subject><subject>Iron - chemistry</subject><subject>iron overload</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Male</subject><subject>MRI</subject><subject>Myocardium - pathology</subject><subject>RR2</subject><subject>thalassemia</subject><subject>Thalassemia - diagnosis</subject><subject>Thalassemia - pathology</subject><subject>Time Factors</subject><issn>1053-1807</issn><issn>1522-2586</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kV1PFDEUhhsjEQRv_AGmd6LJYL87vTEhRBCySLLR4F3T6XSgONOubXdl_73FhY3eeHVOcp7znDYvAK8xOsIIkQ93U_JHhHBOn4E9zAlpCG_F89ojThvcIrkLXuZ8hxBSivEXYJdgrjAiZA-EueuX1vWwJBPyyqXsYHKjuTfFxwCTKQ4ezufkHRxign5apLiqdHYh--JXvqyhD3CKwZeYfLiB0zpak3pvRuhTNdRpuTWjydlN3hyAncGM2b16rPvg2-mnryefm9nV2fnJ8ayxjEvatB0hhOIBMSEYlpx31FIrBsuwEFIxjDppOWNtz0mvlHJY0Z70XIjWiM5iug8-bryLZTe53rpQ_zfqRfKTSWsdjdf_ToK_1TdxpSlSbb1aBW8fBSn-XLpc9OSzdeNogovLrFshJUGCokq-35A2xZyTG7ZXMNIP-eiHfPSffCr85u93bdGnQCqAN8AvP7r1f1T64nJ-_iRtNjs-F3e_3THphxaSSq6vv5xpdT1TF-y70Kf0N2ywq_s</recordid><startdate>201106</startdate><enddate>201106</enddate><creator>Cheung, Jerry S.</creator><creator>Au, Wing-Yan</creator><creator>Ha, Shau-Yin</creator><creator>Kim, Daniel</creator><creator>Jensen, Jens H.</creator><creator>Zhou, Iris Y.</creator><creator>Cheung, Matthew M.</creator><creator>Wu, Yin</creator><creator>Guo, Hua</creator><creator>Khong, Pek-Lan</creator><creator>Brown, Truman R.</creator><creator>Brittenham, Gary M.</creator><creator>Wu, Ed X.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201106</creationdate><title>Reduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia</title><author>Cheung, Jerry S. ; Au, Wing-Yan ; Ha, Shau-Yin ; Kim, Daniel ; Jensen, Jens H. ; Zhou, Iris Y. ; Cheung, Matthew M. ; Wu, Yin ; Guo, Hua ; Khong, Pek-Lan ; Brown, Truman R. ; Brittenham, Gary M. ; Wu, Ed X.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4573-8b22231f046641755b3c3c6fc416679410b7c5448d52d999e193d2d5668a6bc13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Blood Transfusion</topic><topic>cardiac MR</topic><topic>Chelating Agents - pharmacology</topic><topic>chelation therapy</topic><topic>Chelation Therapy - methods</topic><topic>Cytosol - metabolism</topic><topic>Female</topic><topic>ferritin</topic><topic>Ferritins - chemistry</topic><topic>heart</topic><topic>hemosiderin</topic><topic>Hemosiderin - chemistry</topic><topic>Humans</topic><topic>Iron - chemistry</topic><topic>iron overload</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Male</topic><topic>MRI</topic><topic>Myocardium - pathology</topic><topic>RR2</topic><topic>thalassemia</topic><topic>Thalassemia - diagnosis</topic><topic>Thalassemia - pathology</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheung, Jerry S.</creatorcontrib><creatorcontrib>Au, Wing-Yan</creatorcontrib><creatorcontrib>Ha, Shau-Yin</creatorcontrib><creatorcontrib>Kim, Daniel</creatorcontrib><creatorcontrib>Jensen, Jens H.</creatorcontrib><creatorcontrib>Zhou, Iris Y.</creatorcontrib><creatorcontrib>Cheung, Matthew M.</creatorcontrib><creatorcontrib>Wu, Yin</creatorcontrib><creatorcontrib>Guo, Hua</creatorcontrib><creatorcontrib>Khong, Pek-Lan</creatorcontrib><creatorcontrib>Brown, Truman R.</creatorcontrib><creatorcontrib>Brittenham, Gary M.</creatorcontrib><creatorcontrib>Wu, Ed X.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of magnetic resonance imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheung, Jerry S.</au><au>Au, Wing-Yan</au><au>Ha, Shau-Yin</au><au>Kim, Daniel</au><au>Jensen, Jens H.</au><au>Zhou, Iris Y.</au><au>Cheung, Matthew M.</au><au>Wu, Yin</au><au>Guo, Hua</au><au>Khong, Pek-Lan</au><au>Brown, Truman R.</au><au>Brittenham, Gary M.</au><au>Wu, Ed X.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia</atitle><jtitle>Journal of magnetic resonance imaging</jtitle><addtitle>J. Magn. Reson. Imaging</addtitle><date>2011-06</date><risdate>2011</risdate><volume>33</volume><issue>6</issue><spage>1510</spage><epage>1516</epage><pages>1510-1516</pages><issn>1053-1807</issn><eissn>1522-2586</eissn><abstract>Purpose: To evaluate the reduced transverse relaxation rate (RR2), a new relaxation index which has been shown recently to be primarily sensitive to intracellular ferritin iron, as a means of detecting short‐term changes in myocardial storage iron produced by iron‐chelating therapy in transfusion‐dependent thalassemia patients. Materials and Methods: A single‐breathhold multi‐echo fast spin‐echo sequence was implemented at 3 Tesla (T) to estimate RR2 by acquiring signal decays with interecho times of 5, 9 and 13 ms. Transfusion‐dependent thalassemia patients (N = 8) were examined immediately before suspending iron‐chelating therapy for 1 week (Day 0), after a 1‐week suspension of chelation (Day 7), and after a 1‐week resumption of chelation (Day 14). Results: The mean percent changes in RR2, R2, and R2* off chelation (between Day 0 and 7) were 11.9 ± 8.9%, 5.4 ± 7.7% and −4.4 ± 25.0%; and, after resuming chelation (between Day 7 and 14), −10.6 ± 13.9%, −8.9 ± 8.0% and −8.5 ± 24.3%, respectively. Significant differences in R2 and RR2 were observed between Day 0 and 7, and between Day 7 and 14, with the greatest proportional changes in RR2. No significant differences in R2* were found. Conclusion: These initial results demonstrate that significant differences in RR2 are detectable after a single week of changes in iron‐chelating therapy, likely as a result of superior sensitivity to soluble ferritin iron, which is in close equilibrium with the chelatable cytosolic iron pool. RR2 measurement may provide a new means of monitoring the short‐term effectiveness of iron‐chelating agents in patients with myocardial iron overload. J. Magn. Reson. Imaging 2011;33:1510–1516. © 2011 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>21591022</pmid><doi>10.1002/jmri.22553</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1053-1807
ispartof Journal of magnetic resonance imaging, 2011-06, Vol.33 (6), p.1510-1516
issn 1053-1807
1522-2586
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3098046
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content
subjects Adult
Blood Transfusion
cardiac MR
Chelating Agents - pharmacology
chelation therapy
Chelation Therapy - methods
Cytosol - metabolism
Female
ferritin
Ferritins - chemistry
heart
hemosiderin
Hemosiderin - chemistry
Humans
Iron - chemistry
iron overload
Magnetic Resonance Imaging - methods
Male
MRI
Myocardium - pathology
RR2
thalassemia
Thalassemia - diagnosis
Thalassemia - pathology
Time Factors
title Reduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T09%3A52%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduced%20transverse%20relaxation%20rate%20(RR2)%20for%20improved%20sensitivity%20in%20monitoring%20myocardial%20iron%20in%20thalassemia&rft.jtitle=Journal%20of%20magnetic%20resonance%20imaging&rft.au=Cheung,%20Jerry%20S.&rft.date=2011-06&rft.volume=33&rft.issue=6&rft.spage=1510&rft.epage=1516&rft.pages=1510-1516&rft.issn=1053-1807&rft.eissn=1522-2586&rft_id=info:doi/10.1002/jmri.22553&rft_dat=%3Cproquest_pubme%3E867720630%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=867720630&rft_id=info:pmid/21591022&rfr_iscdi=true